Head-to-head · WeighScore
Lumora vs Tablet Health
The verdict
Lumora takes it — 66.1/100 to 47.6/100.
Lumora grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lumora (Blue Skies MD LLC dba Lumora MD) is a physician-founded telehealth platform offering compounded semaglutide and tirzepatide in injectable and sublingual forms.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Lumora | Tablet Health |
|---|---|---|
| WeighScore | 66.1/100 | 47.6/100 |
| Grade | C | C |
| Scorecard rank | #205 | #495 |
| Semaglutide | $199/mo (starting dose, plus a separate fee, compounded) | Not disclosed |
| Tirzepatide | $299/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #205 · C
Strengths
- Compounded semaglutide (5 dose tiers) and tirzepatide (6 dose tiers) in injectable and sublingual forms
- Physician-founded by board-certified Drs. Sean and Shannon Arora (Arora Health & Aesthetics); clinician reviews every assessment
- LegitScript certified, HIPAA compliant, medications dispensed through licensed U.S. pharmacy partners
- Visit fees, medication, labs, and follow-up all included; full pricing shown before commitment
- Peptide therapies offered including NAD+, sermorelin, glutathione, gonadorelin, and PT-141
Where it loses points
- Pricing is fully gated behind the assessment — no public pricing; actual monthly costs unverifiable without completing intake
- Compounded medications are not FDA-approved; compounding pharmacy partners not publicly named
- Newer brand with 2026 founding; no Trustpilot rating or accessible public patient reviews found
- No dietitian, coaching, or HSA/FSA eligibility disclosed on public pages
- Claims all 50 states but 'treatment options may vary by state' with no explicit state-by-state coverage list
Graded #495 · C
Strengths
- LegitScript Certified
- Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
- Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
- Mid-tier pricing starting $179–$299/mo across all four product variants
- No commitment — cancel anytime
Where it loses points
- States served not published — you must complete the intake quiz to learn eligibility
- No founder, CEO, medical director, or pharmacist-in-charge named anywhere
- No BBB profile found
- Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.